Renal Nephroblastoma in a 17-Month-Old Jack Russell Terrier

Abstract

A 17 mo old female Jack Russell terrier was diagnosed with unilateral primary malignant nephroblastoma. The dog presented with polyuria and polydipsia. Laboratory tests revealed polycythemia and elevated serum erythropoietin levels. Diagnostic imaging (i.e., MRI) revealed a unilateral renal mass without spinal cord involvement. Nephrectomy was performed, and the histopathologic diagnosis was nephroblastoma. The dog did not receive any chemotherapy, and there was no evidence of recurrent disease or metastasis over 30 mo after nephrectomy. This is the first case report of a dog presenting with polyuria and polydipsia found to be a result of nephroblastoma. Furthermore, this is the longest survival reported for canine nephroblastoma treated with nephrectomy alone.

Renal nephroblastoma in a 10‐month‐old boxer

“…There are around 20 reported cases of renal nephroblastoma in the veterinary literature (table 5). More recent reports recently had increased survival times, compared with those previously reported (>19,3 >254 and >30 months5). Treatment has varied between cases from nephrectomy alone to nephrectomy with adjunctive chemotherapy (table 5).…”

“…Nephroblastomas have been rarely reported within the veterinary literature, with previous median survival times reported to be 6 months (range 0–6 months) 2. More recent cases have reported significantly longer survival times (>19,3 >254 and >30 months5).…”

Holistic management of renal nephroblastoma in a juvenile dog with severe cachexia: A case report

“…In veterinary medicine, there are no strict recommendations on adjuvant chemotherapy after nephrectomy in renal nephroblastoma, and the reported outcomes are very diverse (5). There are reports of paediatric renal nephroblastoma that were successfully treated with nephrectomy alone (12,17), but they also rapidly metastasized (9) or were multicentric (11). In the present case, adjuvant chemotherapy was recommended despite the early stage (stage I) and favourable histology of the tumour because of the tumour's elevated weight (530 g).…”

Alteraciones hematológicas en pacientes con cáncer: antes, durante y después del tratamiento quimioterapéutico

“…La eritrocitosis es un hallazgo poco común en pacientes con cáncer. Cuando su origen es primario (médula ósea), recibe el nombre de eritrocitosis absoluta primaria; no obstante, también puede ocurrir como consecuencia de síndromes paraneoplásicos, ya sea en neoplasias renales (linfoma, sarcomas, nefroblastoma) o no renales, como schwannoma y leiomiosarcoma cecal (Taylor et al, 2019, Michael et al, 2019Hergt et al, 2019;Yamauchi et al, 2004;Sato et al, 2002).…”